Android Apple

Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent

By Yahoo! Finance   |   1 month ago
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent

Eli Lilly's Phase 3b ADapt study on Ebglyss for atopic dermatitis showed significant improvements in skin and itch, especially for patients previously treated with Dupixent. Results include a high percentage of patients achieving EASI-75 and improved itch relief.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.